Healthy men test generic version of rare disease drug
NCT ID NCT05343715
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 21 times
Summary
This study tested a new version of the drug agalsidase beta (made by Biosidus) against the approved version (Fabrazyme) in 24 healthy men. The goal was to see if the new version behaves similarly in the body. This is an early-stage study that does not directly treat patients with Fabry disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sanatorio Nuestra Señora del Pilar
Ciudadela, Buenos Aires, 1702, Argentina
Conditions
Explore the condition pages connected to this study.